Claims for Patent: 5,750,398

Summary for Patent: 5,750,398

Title:	Vector, element and method for inhibiting immune recognition
Abstract:	This invention relates to the use of Herpes Simplex Virus (HSV) immediate early protein ICP47, nucleic acid sequences coding for ICP47, and homologous proteins and nucleic acid sequences, to inhibit presentation of viral and cellular antigens associated with major histocompatibility class I (MHC class I) proteins to CD8+ T lymphocytes; this inhibition effectively increases infective persistence, which can, for example, improve the utility of viral gene therapy vectors. This invention also pertains to a method for the treatment of herpesvirus infections, wherein expression and/or activity of the ICP47 protein or its homologue is inhibited in order to increase immune recognition of herpesvirus-infected cells and other cells. This invention also pertains to a method for identifying drugs that interfere with the expression or function of ICP47 and its homologues, and which are useful in treating herpesvirus infections, and also pertains to the drugs so identified. Furthermore, this invention pertains to methods for the treatment and prevention of autoimmune diseases, tissue and organ transplant rejection, diabetes, multiple sclerosis, arthritis, and tissue damage accompanying ocular herpesvirus infections, wherein ICP47 or its homologue, or nucleic acids encoding such proteins, are introduced into the cells of a patient. In addition, this invention pertains to vector elements, vectors, polypeptides and polypeptide fragments that can be utilized for the forgoing purposes.
Inventor(s):	Johnson; David C. (Hamilton, Ontario, CA), York; Ian A. (Hamilton, Ontario, CA)
Assignee:	Johnson; David C. (Portland, OR) York; Ian A. (Worcester, MA)
Application Number:	08/159,890
Patent Claims:	1. A method for inhibiting cell recognition by cytotoxic T lymphocytes, comprising introducing into a mammalian cell an isolated nucleotide sequence encoding a herpes simplex virus protein which inhibits the ability of said cell to present antigens associated with MHC class I proteins to T lymphocytes. 2. The method of claim 1 wherein the herpes simplex virus protein which inhibits antigen presentation by said cell is selected from the group consisting of ICP47 of HSV-1 and IE12 of HSV-2. 3. The method of claim 1 wherein the herpes simplex virus protein which inhibits antigen presentation by said cell is ICP47 of HSV-1. 4. The method according to claim 1 wherein the nucleotide sequence is introduced through the use of a viral vector. 5. The method according to claim 1 wherein the nucleotide sequence is introduced through the use of a viral vector separate from and in addition to a expression vector with which the cell is also infected. 6. A recombinant expression vector comprising a promoter operably linked to a nucleotide sequence encoding an HSV-1 ICP47 protein or an HSV-2 IE12 protein, which expression vector, when present in a mammalian cell, inhibits the ability of said cell to present antigens associated with MHC class I proteins to T lymphocytes, and so inhibits recognition of said cell by cytotoxic T lymphocytes. 7. An expression vector according to claim 6 wherein the nucleotide sequence encoding an HSV-1 ICP47 protein comprises the 714 bp NruI-XhoI fragment of pRHP6, including part of the first exon, the intron, and the entire coding sequences of ICP47. 8. An expression vector according to claim 6 which is a recombinant viral expression vector. 9. A vector according to claim 8 wherein said vector is ADICP47-1, or wherein said vector has the activity of ADICP47-1 of inhibiting the ability of a mammalian cell to present antigens associated with MHC class I proteins to T lymphocytes, and so inhibiting recognition of said cell by cytotoxic T lymphocytes, when present in said cell.

Details for Patent 5,750,398

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26